CCND1 and neoplasm: Silencing of CTBP2 markedly increases apoptosis of prostate cancer cells; decreases the expression of IL-8, AT2R, CCND1, MMP9, MYC, and HSPC111; and reduces tumor growth in mouse xenograft model of human prostate cancer [32,33,34,35,36].